Photys Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Induced Proximity PHICS Technology for Cardiometabolic Diseases
Portfolio Pulse from
Photys Therapeutics has entered a multi-year collaboration with Novo Nordisk to develop proximity-based therapeutics for cardiometabolic diseases using PHICS technology. The deal could be worth up to $186 million, including milestone payments and royalties.

December 18, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk has partnered with Photys Therapeutics to develop new treatments for cardiometabolic diseases using PHICS technology. The collaboration could be worth up to $186 million.
The partnership with Photys Therapeutics could enhance Novo Nordisk's pipeline in cardiometabolic diseases, potentially leading to new product offerings and revenue streams. The financial terms suggest significant investment and potential returns.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80